Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 2000 Jan 25;162(2):195–198.

To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy

W F Clark 1, D N Churchill 1, L Forwell 1, G Macdonald 1, S Foster 1
PMCID: PMC1232268  PMID: 10674051

Abstract

BACKGROUND: Angiotensin-converting-enzyme (ACE) inhibitor therapy can significantly delay the progression of diabetic nephropathy to end-stage renal failure (ESRF). The main obstacle to successful compliance with this therapy is the cost to the patients. The authors performed a cost-utility analysis from the government's perspective to see whether the province or territory should pay for ACE inhibitors for type I diabetic nephropathy on the assumption that cost is a major barrier to compliance with this important therapy. METHODS: A decision analysis tree was created to demonstrate the progression of type I diabetes with macroproteinuria from the point of prescription of ACE inhibitor therapy through to ESRF management, with a 21-year follow-up. Drug compliance, cost of ESRF treatment, utilities and survival data were taken from Canadian sources and used in the cost-utility analysis. One-way and two-way sensitivity analyses were performed to test the robustness of the findings. RESULTS: Compared with a no-payment strategy, provincial payment of ACE inhibitor therapy was found to be highly cost-effective: it resulted in an increase of 0.147 in the number of quality-adjusted life-years (QALYs) and an annual cost savings of $849 per patient. The sensitivity analyses indicated that the cost-effectiveness depends on compliance, effect of benefit and the cost of drug therapy. Changes in the compliance rate from 67% to 51% could result in a swing in cost-effectiveness from a savings of $899 to an expenditure of more than $1 million per additional QALY. A 50% reduction in the cost of ACE inhibitors would result in a cost savings of $299 per additional QALY with compliance rates as low as 58% in the provincial payment strategy. INTERPRETATION: Provincial coverage of ACE inhibitor therapy for type I diabetes with macroproteinuria improves patient outcomes, with a decrease in cost for ESRF services.

Full Text

The Full Text of this article is available as a PDF (249.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becker G. J., Whitworth J. A., Ihle B. U., Shahinfar S., Kincaid-Smith P. S. Prevention of progression in non-diabetic chronic renal failure. Kidney Int Suppl. 1994 Feb;45:S167–S170. [PubMed] [Google Scholar]
  2. Borch-Johnsen K. ACE inhibitors in patients with diabetes mellitus. Clinical and economic considerations. Pharmacoeconomics. 1996 May;9(5):392–398. doi: 10.2165/00019053-199609050-00003. [DOI] [PubMed] [Google Scholar]
  3. Brand F. N., Smith R. T., Brand P. A. Effect of economic barriers to medical care on patients' noncompliance. Public Health Rep. 1977 Jan-Feb;92(1):72–78. [PMC free article] [PubMed] [Google Scholar]
  4. Churchill D. N., Torrance G. W., Taylor D. W., Barnes C. C., Ludwin D., Shimizu A., Smith E. K. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med. 1987 Jan;10(1):14–20. [PubMed] [Google Scholar]
  5. Eraker S. A., Kirscht J. P., Becker M. H. Understanding and improving patient compliance. Ann Intern Med. 1984 Feb;100(2):258–268. doi: 10.7326/0003-4819-100-2-258. [DOI] [PubMed] [Google Scholar]
  6. Gibaldi M. Failure to comply: a therapeutic dilemma and the bane of clinical trials. J Clin Pharmacol. 1996 Aug;36(8):674–682. doi: 10.1002/j.1552-4604.1996.tb04235.x. [DOI] [PubMed] [Google Scholar]
  7. Goeree R., Manalich J., Grootendorst P., Beecroft M. L., Churchill D. N. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med. 1995 Dec;18(6):455–464. [PubMed] [Google Scholar]
  8. Hilleman D. E., Mohiuddin S. M., Lucas B. D., Jr, Stading J. A., Stoysich A. M., Ryschon K. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther. 1994 Jan-Feb;16(1):88–87. [PubMed] [Google Scholar]
  9. Koch M., Thomas B., Tschöpe W., Ritz E. Diabetes mellitus accounts for an ever-increasing proportion of the patients admitted for renal replacement therapy. Nephrol Dial Transplant. 1989;4(5):399–399. doi: 10.1093/oxfordjournals.ndt.a091899. [DOI] [PubMed] [Google Scholar]
  10. Laffel L. M., McGill J. B., Gans D. J. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995 Nov;99(5):497–504. doi: 10.1016/s0002-9343(99)80226-5. [DOI] [PubMed] [Google Scholar]
  11. Laupacis A., Keown P., Pus N., Krueger H., Ferguson B., Wong C., Muirhead N. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996 Jul;50(1):235–242. doi: 10.1038/ki.1996.307. [DOI] [PubMed] [Google Scholar]
  12. Leibowitz A., Manning W. G., Newhouse J. P. The demand for prescription drugs as a function of cost-sharing. Soc Sci Med. 1985;21(10):1063–1069. doi: 10.1016/0277-9536(85)90161-3. [DOI] [PubMed] [Google Scholar]
  13. Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456–1462. doi: 10.1056/NEJM199311113292004. [DOI] [PubMed] [Google Scholar]
  14. Manning W. G., Newhouse J. P., Duan N., Keeler E. B., Leibowitz A., Marquis M. S. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987 Jun;77(3):251–277. [PubMed] [Google Scholar]
  15. Maschio G., Alberti D., Janin G., Locatelli F., Mann J. F., Motolese M., Ponticelli C., Ritz E., Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996 Apr 11;334(15):939–945. doi: 10.1056/NEJM199604113341502. [DOI] [PubMed] [Google Scholar]
  16. McKenney J. M., Munroe W. P., Wright J. T., Jr Impact of an electronic medication compliance aid on long-term blood pressure control. J Clin Pharmacol. 1992 Mar;32(3):277–283. doi: 10.1002/j.1552-4604.1992.tb03837.x. [DOI] [PubMed] [Google Scholar]
  17. O'Brien B. The effect of patient charges on the utilisation of prescription medicines. J Health Econ. 1989 Mar;8(1):109–132. doi: 10.1016/0167-6296(89)90011-8. [DOI] [PubMed] [Google Scholar]
  18. Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993 Apr 15;118(8):577–581. doi: 10.7326/0003-4819-118-8-199304150-00001. [DOI] [PubMed] [Google Scholar]
  19. Soumerai S. B., Avorn J., Ross-Degnan D., Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987 Aug 27;317(9):550–556. doi: 10.1056/NEJM198708273170906. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES